Pyridine-2-thiol 1-oxide, sodium salt

Acute Toxicity: inhalation

Administrative data

Endpoint:

acute toxicity: inhalation

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1987

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

EPA OPP 81-3 (Acute inhalation toxicity)

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.2 (Acute Toxicity (Inhalation))

GLP compliance:

yes

Test material

Test material information

Constituent 1

Reference substance name:

Pyridine-2-thiol 1-oxide, sodium salt

EC Number:

223-296-5

EC Name:

Pyridine-2-thiol 1-oxide, sodium salt

Cas Number:

3811-73-2

Molecular formula:

C5H5NOS.Na

IUPAC Name:

sodium (1-oxo-1λ⁵-pyridin-2-yl)sulfanide

Details on test material:

- Analytical purity: 43.78%
- Lot/batch No.: F113D1

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

-Source: Charles River Laboratories
-Age: 7-10 weeks
Weight: Male 237-292g, female 178-220g

Administration / exposure

Route of administration:

inhalation: aerosol

Type of inhalation exposure:

whole body

Vehicle:

other: unchanged (no vehicle)

Details on inhalation exposure:

-Post exposure period: 14 days

Duration of exposure:

4 h

Concentrations:

-Nominal concentrations: 6.6, 8.1, 18.6, 23.7, and 25.9 mg/L
-Analytical concentrations: 0.14, 0.58, 0.79, 0.95, and 1.4 mg/L
Particle sizes:
MMAD 2.3, 2.5, 3.0, 3.2, and 2.5 µm
+ GSD 2.28, 1.92, 1.95, 2.00, and 1.92 µm

No. of animals per sex per dose:

5

Details on study design:

-Preparation of aerosol: Test material was generated as a liquid aerosol with a positive displacement pump to a pneumatic atomizer operated with compressed air. The liquid droplet aerosol was delivered at a constant rate to the external 4-liter glass atomization chamber. Compressed air was used to dilute the aerosol to the test concentration and swept into the exposure chamber.

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LC50

Effect level:

1.08 mg/L air

Mortality:

Mortality: 0/5 males and 0/5 females exposed to 0.14 mg/L
0/5 males and 2/5 females exposed to 0.58 mg/L
3/5 males and 5/5 females exposed to 0.79 mg/L
0/5 males and 1/5 females exposed to 0.95 mg/L
3/5 males and 3/5 females exposed to 1.4 mg/L

Clinical signs:

other: Toxicologically significant clinical signs on the day of exposure were death, prostration, excess salivation, and red material around eyes and nose. Observations during the 14-day post-exposure period were death, decrease in body weight gain (top 3 dose

Body weight:

The average body weight gain was depressed during the two weeks post-exposure for the top 3 doses only in the males and for all doses tested in females.

Gross pathology:

Exposure related abnormalities were limited to the respiratory tract and were characterized as congestion. Accumulation of the test material was also noted in the trachea and esophagus.

Applicant's summary and conclusion

Conclusions:

A combined LC50 value (males + females) of 1.08 mg/L (95% confidence limits = 0.71 – 1.66 mg/L). The information contained within this robust summary document comes from studies which are in the ownership of Arch Chemicals Inc. and which are protected in several regions globally. This information may not be used for any purpose other than in support of the Chemical safety Report submitted by Arch Chemicals Inc. under Regulation EC 1907/2006.